[educational] A 29-amino-acid GHRH analog (GRF 1-29), FDA-approved historically for short stature; used off-label to augment endogenous GH/IGF-1. Framed as the gentle, physiologic “starter” GH secretagogue — meant to augment natural pulsatility, not max out GH. ~3–4× cheaper than tesamorelin. — GH admin guide
[educational] Human data: 1 mg ×2/day raised GH significantly (0.5 mg did not); a sermorelin-analog study dosed ~10 mcg/kg/day. CJC-1295-without-DAC is ~4× more potent (4-aa modification of sermorelin). Long-term sermorelin-analog data showed declining response after 12–16 weeks (rationale for cycling). — GH admin guide
[educational] ~100 adults across small studies: ~+50% IGF-1 with body-comp gains, and notably improves insulin sensitivity (vs tesamorelin’s early worsening). First GHRH analog (1980s); the gentle/physiologic starter. — GH selection guide
Anecdotes
Physician protocols
[protocol] SubQ (oral ≈ 0% bioavailable). Anecdotal start 200–300 mcg, work to 500 mcg, theoretical max 1 mg. If no benefit by ~500 mcg, switch to CJC-1295-no-DAC (more cost-effective) rather than maxing. Dose at night, right before sleep, no food ~4 h prior (food blunts GH ~60%). 5 days on / 2 off, ~3–4 months on / 1 month off. Educational only; with your doctor. — GH admin guide
Practical notes
[educational] Monitor IGF-1 (keep in range, not too high), insulin/glucose/A1C, lipids, prolactin, thyroid, cortisol; cancer screening before starting. — GH admin guide